54gene
closedDate | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$150k | Seed | ||
$4.5m | Seed | ||
* | $15.0m | Series A | |
$25.0m | Series B | ||
* | $50.0m | Convertible | |
* | N/A | N/A | Bankruptcy |
Total Funding | $94.7m |
Related Content
Recent News about 54gene
Edit54gene is a health technology company focused on advancing African genomics to improve health outcomes globally. The company operates in three synergistic business lines: drug discovery, molecular diagnostics, and clinical trial programs. These lines of business are specifically inclusive of African populations, demonstrating a strong commitment to Africa and partnering with other mission-driven organizations to enable global access to precision medicine.
54gene serves pharmaceutical companies, biotech firms, and research institutions looking to leverage African genetic data for drug development and precision medicine. The company operates in the healthcare and biotechnology markets, utilizing a business model that combines service fees from clinical trials, licensing fees from drug discoveries, and sales from molecular diagnostic tests.
Revenue is generated through partnerships with global pharmaceutical companies, biotech firms, and research institutions, as well as through the commercialization of its proprietary molecular diagnostic tests.
Keywords: African genomics, drug discovery, molecular diagnostics, clinical trials, precision medicine, healthcare technology, biotech, pharmaceutical partnerships, genetic data, health outcomes.